Milan-based Newronika, a company specialising in advanced deep brain stimulation, has closed a €13.6M Series B funding round.
The Italian company develops an adaptive deep brain stimulation (DBS) platform that adjusts therapy based on real-time patient data. It focuses on advancing neuromodulation beyond current methods.
Neuromodulation is a treatment that uses electrical or chemical stimulation to help manage neurological disorders and enhance patient well-being.
Newronika’s recent funding, along with a grant from The Michael J. Fox Foundation and IDE approval, highlights its advancements in neuromodulation. The company has a CE Mark, FDA Investigational Device Exemption, and active research collaborations in neurological treatment.
Investors supporting Newronika
The round was led by new investor Fondazione ENEA Tech e Biomedical, with participation from existing investors Indaco Venture Partners SGR, Innogest Capital SGR, Wille Finance, TNBT Capital, and F3F.
Maria Cristina Porta, ENEA Tech e Biomedical General Manager, says, “With Newronika and its adaptive DBS platform, we see extraordinary potential to revolutionise the treatment of movement disorders on a global scale. Their innovative approach, capable of real-time, personalised neuromodulation, perfectly aligns with our vision of supporting disruptive medical technologies.”
“We are excited to partner with Newronika to deliver next-generation DBS solutions to patients in need. Investing in technologies like this means caring for people’s health while creating value and driving innovation within our country’s ecosystem.”
CEO of Indaco, Davide Turco, adds, “Indaco is proud to continue supporting Newronika, also through its Indaco Venture I – Lombardia Parallel Fund, in the upcoming clinical and commercial phases. We strongly believe that Newronika’s adaptive DBS system will improve the quality of life for many Parkinson’s patients.”
Capital utilisation
Newronika plans to use the funds to advance the clinical validation and commercialisation of its adaptive deep brain stimulation (DBS) system.
The investment will also support product development, talent acquisition, and strategic collaborations to enhance the company’s position in medical device engineering and neuroscience.
Dr. Lorenzo Rossi, co-founder and CEO of Newronika, says, “We are thrilled with the strong support from both new and existing investors. This Series B round validates our commitment to transform the way deep brain stimulation is delivered.”
“We aim to seamlessly integrate real-time neural data and machine learning into our DBS systems to create truly personalised therapies that surpass the capabilities of existing devices on the market.”
01
How Gen Z affects B2B social media